Truist analyst David MacDonald raised the firm’s price target on Tenet Healthcare to $170 from $155 and keeps a Buy rating on the shares. The company’s Q2 results were marked by top and bottom-line beats, solid Hospital volumes, brisk revenue and case growth and continued labor improvement, the analyst tells investors in a research note. Tenet’s financial flexibility remains solid and its leverage has improved meaningfully, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare raises FY24 adjusted EPS view to $10.41-$11.12 from $8.37-$9.41
- Tenet Healthcare sees Q3 adjusted EPS $2.16-$2.58
- Tenet Healthcare announces new $1.5B share repurchase program
- Tenet Healthcare reports Q2 adjusted EPS $2.31 vs. $1.44 last year
- THC Earnings this Week: How Will it Perform?